New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine

Abstract

Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD.

Keywords:

• quetiapine
• major depressive disorders
• general anxiety disorder
• randomized controlled studies
• adverse effects

Acknowledgments

The author is grateful for the contribution of Veronica DuBois and Riccardo Caniato during the editing process of the manuscript.

Disclosures

BT Baune has received grants from the National Health and Medical Research Council (NHMRC, Australia). He has received honoraria (<$1,000 US from each) for educational training of psychiatrists and general practitioners from Lundbeck, Astra Zeneca and Pfizer Pharmaceuticals. He has received travel grants for attending congresses from Astra Zeneca, Bristol-Meyer Squibb, Janssen and Pfizer Pharmaceuticals. The author declares no conflict of interest.